Charles River Laboratories Intl. Inc vs Clear Secure Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $303.31 (market cap $14.23B), while Clear Secure Inc trades at $43.49 (market cap $4.44B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.2× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Clear Secure Inc for 19 Days on average.
| CRL | YOU | |
|---|---|---|
Market Cap | $14.23B | $4.44B |
Volume | 1,176,885 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $310.77 | $62.36 |
52-Week Low | $149.93 | $29.61 |
Typical Hold Time | 33 Days | 19 Days |
Enterprise Value | $17.06B | $3.59B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Clear Secure (YOU) trades at $43.26, up 1.59% today, with a bullish technical signal despite mixed moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Profitability remains robust with a net margin of 14.78% and ROE of 90.29%, though valuation multiples like P/E of 29.11 appear elevated. Recent news highlights strategic partnerships, such as the integration with CrowdStrike's Falcon platform, and the launch of corporate memberships.
The outlook is positive given earnings momentum and expanding market opportunities, but risks include high valuation sensitivity and competitive pressures. Analysts are generally bullish with a consensus price target of $61.40, implying significant upside, though insider selling and overbought RSI levels warrant caution for near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →